NEW YORK — Interpace Diagnostics said today that it has signed coverage contracts with three independent Blue Cross Blue Shield plans in Alabama, Arkansas, and Arizona for its ThyGeNext and ThyraMir thyroid cancer detection assays on an in-network basis.
The BCBS plans cover nearly 5 million individuals in the three states, Parsippany, New Jersey-based Interpace said.